Abbott Submits Humira sBLA for Juvenile Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, Humira would compete directly with Wyeth/Amgen’s Enbrel in the indication.
You may also be interested in...
Abbott’s Humira Approved For Juvenile Idiopathic Arthritis
Tumor necrosis factor inhibitor an important option to Wyeth’s Enbrel, Abbott tells “The Pink Sheet” DAILY.
Abbott’s Humira Approved For Juvenile Idiopathic Arthritis
Tumor necrosis factor inhibitor an important option to Wyeth’s Enbrel, Abbott tells “The Pink Sheet” DAILY.
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.